Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...
Disease modifying mechanism of action: short treatment course results in significant and durable clinical response in psoriasis patients si-544 is the first highly potent and selective Kv1.3 blocker ...
Gut microbiota as a biomarker for the efficacy of pembrolizumab in patients with advanced urothelial carcinoma treated in a prospective multicenter study. NECTIN4 RNA expression and clinical outcomes ...
Merus N.V., an oncology-focused company, announced the publication of research on petosemtamab, a bispecific antibody targeting EGFR and LGR5, in the journal "Cancers." The study highlights the ...
Vomiting 2.5 5.9 8.5 Vision blurred 2.5 2.2 8.5 Somnolence 4.7 5.2 8.1 Nasopharyngitis 5.8 6.3 7.6 Fatigue 5.8 7.0 7.2 Coordination abnormal 1.6 4.1 7.2 Tremor 4.1 3.7 6.2 Balance disorder 0.0 1.1 5.1 ...
New animal research being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), reveals distinct metabolic adjustments to tirzepatide and semaglutide treatment, ...
Race identifies primary mechanism of action for (E,E)-bisantrene (RCDS1), the active compound underpinning its lead candidate RC220 drug Targeting G4-DNA and RNA structures by RCDS1 reduces the ...
Please provide your email address to receive an email when new articles are posted on .
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback